File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Randomized, prospective, and double-blind trial of new β-lactams in the treatment of appendicitis

TitleRandomized, prospective, and double-blind trial of new β-lactams in the treatment of appendicitis
Authors
Issue Date1985
Citation
Antimicrobial Agents And Chemotherapy, 1985, v. 28 n. 5, p. 639-642 How to Cite?
AbstractA prospective, randomized and double-blind study was conducted with 864 patients operated on for appendicitis. In early cases, including normal and acute appendicitis, one dose of antibiotic was given. The rate of postappendectomy septic complications in patients who received cefotaxime, cefoperazone, or moxalactam was very low (about 3%), and there was not statistical difference between the drugs. For late cases, including gangrenous and perforated appendicitis, the antibiotics were continued for 5 days. Moxalactam decreased significantly the septic complications in these patients when compared with the other two drugs. It is safe, free from serious toxic side effects, and more convenient and easier to administer than combination antibiotic therapy. The main disadvantage of moxalactam is its high cost, but this has to be balanced against the savings in nursing time, the cost of monitoring renal function and serum level when aminoglycosides are used, and the reduced usage and manipulation of infusion sets.
Persistent Identifierhttp://hdl.handle.net/10722/172542
ISSN
2015 Impact Factor: 4.415
2015 SCImago Journal Rankings: 2.322
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, WYen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorChu, KWen_US
dc.date.accessioned2012-10-30T06:23:19Z-
dc.date.available2012-10-30T06:23:19Z-
dc.date.issued1985en_US
dc.identifier.citationAntimicrobial Agents And Chemotherapy, 1985, v. 28 n. 5, p. 639-642en_US
dc.identifier.issn0066-4804en_US
dc.identifier.urihttp://hdl.handle.net/10722/172542-
dc.description.abstractA prospective, randomized and double-blind study was conducted with 864 patients operated on for appendicitis. In early cases, including normal and acute appendicitis, one dose of antibiotic was given. The rate of postappendectomy septic complications in patients who received cefotaxime, cefoperazone, or moxalactam was very low (about 3%), and there was not statistical difference between the drugs. For late cases, including gangrenous and perforated appendicitis, the antibiotics were continued for 5 days. Moxalactam decreased significantly the septic complications in these patients when compared with the other two drugs. It is safe, free from serious toxic side effects, and more convenient and easier to administer than combination antibiotic therapy. The main disadvantage of moxalactam is its high cost, but this has to be balanced against the savings in nursing time, the cost of monitoring renal function and serum level when aminoglycosides are used, and the reduced usage and manipulation of infusion sets.en_US
dc.languageengen_US
dc.relation.ispartofAntimicrobial Agents and Chemotherapyen_US
dc.subject.meshAnti-Bacterial Agents - Therapeutic Useen_US
dc.subject.meshAppendectomyen_US
dc.subject.meshCefoperazone - Therapeutic Useen_US
dc.subject.meshCefotaxime - Therapeutic Useen_US
dc.subject.meshChilden_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshHumansen_US
dc.subject.meshKineticsen_US
dc.subject.meshMoxalactam - Therapeutic Useen_US
dc.subject.meshPremedicationen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshSurgical Wound Infection - Prevention & Controlen_US
dc.titleRandomized, prospective, and double-blind trial of new β-lactams in the treatment of appendicitisen_US
dc.typeArticleen_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1128/AAC.28.5.639-
dc.identifier.pmid3911877-
dc.identifier.scopuseid_2-s2.0-0022402004en_US
dc.identifier.volume28en_US
dc.identifier.issue5en_US
dc.identifier.spage639en_US
dc.identifier.epage642en_US
dc.identifier.isiWOS:A1985ATX7100009-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLau, WY=7402933199en_US
dc.identifier.scopusauthoridFan, ST=7402678224en_US
dc.identifier.scopusauthoridChu, KW=16026609700en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats